Stock comparison
BioCryst Pharmaceuticals
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BCRX
BioCryst Pharmaceuticals
Market cap
$1.89B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.41B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BCRX | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 40D | 79B | HALO |
| Benjamin Graham | 24F | 83A | HALO |
| Philip Fisher | 40D | 65B | HALO |
| Peter Lynch | 60C | 53D | BCRX |
| Joel Greenblatt | 4F | 40D | HALO |
| Charlie Munger | 35D | 80C | HALO |
| Terry Smith | 41D | 84A | HALO |
Side-by-side metrics
| Metric | BCRX | HALO |
|---|---|---|
| Market cap | $1.89B | $8.41B |
| P/E (TTM) | - | 24.0x |
| EV/EBIT | 7.6x | 10.2x |
| ROIC (TTM) | -121.96% | 23.65% |
| Gross margin | 18.89% | 81.24% |
| Net margin | -51.71% | 23.13% |
| Revenue CAGR 5y | 53.6% | 33.23% |
| EPS CAGR 5y | - | -1.98% |
| Debt / Equity | - | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BCRX leads on
- Debt / Equity-vs 1.0x+161%
- P/E (TTM)-vs 24.0x+120%
- Revenue CAGR 5y53.6%vs 33.23%+38%
- EV/EBIT7.6xvs 10.2x+26%
HALO leads on
- Net margin23.13%vs -51.71%+145%
- ROIC (TTM)23.65%vs -121.96%+119%
- Market cap$8.41Bvs $1.89B+77%
- Gross margin81.24%vs 18.89%+77%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.